- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Asciminib, as a novel kinase inhibitor targeting BCR-ABL1 protein, requires individualized medication plans based on physiological status and o...
The use of Asciminib should pay attention to the management of missed doses, monitoring of adverse reactions, and dietary taboos. The precautio...
The usage and dosage of Enasidenib should strictly follow the standard protocol, while paying attention to specific food taboos to avoid drug ...
Enasidenib, as an IDH2 inhibitor, needs to be adjusted according to physiological status and organ function when used in special populations, w...
Venetoclax, as a BCL-2 inhibitor, commonly has side effects such as bone marrow suppression, gastrointestinal reactions, and tumor lysis syndro...
Venetoclax, as a BCL-2 inhibitor, needs to be adjusted according to physiological status and organ function when used in special populations. T...
The use of Infiglatinib in special populations needs to be adjusted based on pregnancy, lactation, liver and kidney function, and strict risk a...
Infiglatinib, as an FGFR inhibitor, commonly has side effects such as eye, skin, and electrolyte imbalances. Targeted monitoring and interventi...
The side effects of Ixazomib include blood system abnormalities, gastrointestinal reactions, peripheral neuropathy, etc., which need to be al...
Ixazomib, as a proteasome inhibitor, varies in efficacy depending on individual differences. It usually requires continuous medication for 2-4 ...
